导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.03% | 1045/2676 |
| 近一周 | -0.94% | 792/3004 |
| 近一月 | -1.10% | 552/2984 |
| 近一季 | -3.22% | 902/2896 |
| 近半年 | -4.70% | 1609/2746 |
| 近一年 | 5.21% | 951/2519 |
| 近两年 | 30.70% | 1355/1796 |
| 近三年 | 18.93% | 883/1340 |
| 成立以来 | 63.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.25% 1593/4961 |
7.63% 2682/5312 |
- - |
- - |
| 2025 | 6.27% 2969/4813 |
-4.90% 3234/3635 |
1.15% 2444/4076 |
10.27% 3307/4524 |
0.19% 2145/4813 |
| 2024 | 15.86% 868/3463 |
4.93% 415/2808 |
2.10% 404/3014 |
8.67% 2730/3129 |
-0.48% 1437/3463 |
| 2023 | 1.68% 353/2656 |
12.42% 294/2280 |
-0.71% 408/2385 |
-4.71% 1208/2515 |
-4.40% 1012/2655 |
| 2022 | -14.68% 384/2207 |
-12.02% 565/1919 |
3.51% 1142/2016 |
-9.80% 310/2113 |
3.87% 624/2208 |
| 2021 | 16.14% 279/1822 |
-0.25% 344/1255 |
4.70% 854/1330 |
8.94% 151/1466 |
2.07% 707/1822 |
| 2020 | 15.08% 784/1250 |
-10.12% 757/1028 |
4.85% 899/1067 |
9.32% 657/1164 |
11.69% 526/1184 |
| 2019 | 5.79% 746/1092 |
12.08% 711/739 |
-6.99% 534/788 |
-1.27% 640/850 |
2.79% 858/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证央企ETF联接A VS. 长安沪深300非周期A(740101) |